Why Summit Therapeutics Inc.’s (SMMT) Stock Is Down 6.90%
As of Tuesday, November 17, Summit Therapeutics Inc.’s SMMT share price has dipped by 6.90%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
Michael Rose
Michael Rose
| Share Statistics | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,397.5 | $213.9 | 76% |
|
| Shares Out (Mil) | 798.2 | 55.4 | 92% |
|
| Institutional Ownership | 18.3% | 93.3% | 9% |
|
| Float (Mil) | 153.7 | 40.6 | 69% |
|
| Beta | -1.52 | 0.98 | 0% |
|
| Avg Daily Volume (000s) | 8,651 | 597 | 95% |
|
| Price Change (52-week) |
(38.1%) | 40.9% | 26% |
|
| Growth | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (82.9%) | (10.7%) | 3% |
|
| EPS (5yr) | (13.7%) | 15.5% | 19 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 32.0% | (15.7%) | 87% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 9 | na | |
| Current EPS | ($0.266) | ($1.038) | na | |
| Month Ago EPS | ($0.341) | ($1.110) | na | |
| # Rev Up | 0 | 0 | na | |
| # Rev Down | 0 | 1 | na | |
| Three Months Ago EPS | ($0.333) | ($1.132) | na | |
| Year/Year Chg | 1.9% | (28.1%) | (28.0%) | |
| Financials | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($833) | ($44) | 2% |
|
| EPS (TTM) | ($1.068) | ($1.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($525) | ($34) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($88) | $-0 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $4 | 31% |
|
| Enterprise Value (Q1) (Mil) | $12,450 | $135 | 77% |
|
| Valuation | SMMT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 14.79 | 1.97 | 95% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | SMMT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (174.5%) | (47.5%) | 2% |
|
| ROE | (220.0%) | (51.9%) | 4% |
|
| Liabilities to Assets | 18.5% | 29.7% | 12% |
|
| F-Score | 3 | 3 | 18% |
|
Summit Therapeutics Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors